Ardent Health price target raised to $22 from $21 at Truist

Truist analyst David MacDonald raised the firm’s price target on Ardent Health to $22 from $21 and keeps a Buy rating on the shares. The firm is bullish on Ardent Health following Q2 results which featured top-line/volume strength and solid cost controls, driving an adjusted EBITDA beat with margins ahead of Truist’s projections, the analyst tells investors in a research note. Ardent’s initial FY guidance also captured consensus estimates and incorporates continued solid volume growth, the firm added.